Biomedical subjects

K K Teo

Publications and source records attributed to K K Teo.

116 records · Page 7Linked to original sources

PubMedDate not supplied

Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria.

This paper discusses the various philosophies that influence the selection of patients for entry into randomized controlled trials. Although a number of different and often competing issues have to be considered depending upon the trial, keeping entry criteria simple, wide and at times even flexible is usually preferable. Such a strategy can be a positive virtue by helping to attain the large numbers of patients that are usually needed to reliably detect the sorts of moderate benefits that are plausible, at a reasonable cost and by providing answers that are relevant to many different categories of patients with a particular condition.

Bias↗

PubMedDate not supplied

A review of impedance cardiography.

OBJECTIVE: To review the reliability and validity estimates of impedance cardiography to assess its empirical precision and clinical usefulness. DATA SOURCE: Empirical and theoretical literature mainly within the last 10 years. DATA SYNTHESIS: Descriptive statistics used to summarize the accuracy and use of impedance cardiography to estimate stroke volume. CONCLUSIONS: Estimation of cardiac output is presently a core component of optimizing cardiac function in many patient populations. Impedance cardiography, which initially used a formula developed by Kubicek et al. and recently a formula developed by Sramek and Bernstein, remains controversial with regard to its accuracy and use in research and clinical practice.

Cardiac Output↗

PubMedDate not supplied

Therapy of angina pectoris with low-dose perhexiline.

We conducted a double-blind, crossover study into the effect of 100 mg of perhexiline maleate twice daily on the response to exercise of 15 patients with proven ischemic heart disease. Patients were evaluated by bicycle ergometry, on three occasions, before treatment and after 2 weeks of treatment with placebo or perhexiline. Patients were able to exercise for a longer period as shown by comparing perhexiline to pretreatment (mean change, 54.9%; p less than 0.001) and placebo values (38.9%; p less than 0.001). An increase in work performed while taking perhexiline was demonstrated when compared to pretreatment (mean change, 29.7%; p less than 0.001) and placebo (26.3%; p less than 0.001). An increase in heart rate at maximal exercise was observed when compared to pretreatment (mean change, 9.7%; p less than 0.01) and placebo (8.8%; p less than 0.01). A reduction in heart rate for a given workload was obtained when compared to pretreatment (mean change, 7.0%; p less than 0.005) and placebo (2.9%; p less than 0.01). An increase in resting systolic blood pressure while taking perhexiline was shown when compared to pretreatment (mean change, 12.8%; p less than 0.02) and placebo measurements (8.5%; p less than 0.05). Perhexiline in a dose of 200 mg daily is effective against angina pectoris and significantly increases exercise tolerance. The likelihood of side effects may be decreased by using this dosage regimen.

Adult↗

PubMedDate not supplied

Training response in patients with coronary artery disease receiving beta-adrenergic blocking drugs with or without partial agonist activity.

It has been suggested that beta-adrenoceptor blocking agents may impair the training response but that this may not occur if the agent possesses partial agonist activity (PAA). We tested these hypotheses in 39 male patients, following myocardial infarction or coronary artery bypass graft surgery, who underwent structured exercise training three times a week for 8 weeks. Exercise tolerance was assessed before training, within 5 days after training, and again 2 weeks after training in 14 patients receiving acebutolol (with PAA), 12 patients receiving sotalol (without PAA), and 13 patients receiving placebo. Blood levels of both agents confirmed that steady states sufficient to produce beta-blockade were achieved during training. All three groups of patients demonstrated statistically significant improvements in exercise duration, energy expenditure, heart rates attained performing equal work loads, and percentage functional aerobic impairment. No significant differences were found between the three groups before or after training. We conclude that beta-adrenoceptor blocking agents in standard therapeutic doses do not cause impairment of exercise training and that PAA affords no enhancement of the training response.

Acebutolol↗

PubMedDate not supplied

Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE).

Cardiovascular disease rates vary greatly between ethnic groups in Canada. To establish whether this variation can be explained by differences in disease risk factors and subclinical atherosclerosis, we undertook a population-based study of three ethnic groups in Canada: South Asians, Chinese and Europeans. A total of 985 participants were recruited from three cities (Hamilton, Toronto and Edmonton) by stratified random sampling. Clinical cardiovascular disease was defined by history or electrocardiographic findings. Carotid atherosclerosis was measured with B-mode ultrasonography. Conventional (smoking, hypertension, diabetes, raised cholesterol) and novel risk factors (markers of a prothrombotic state) were measured. Within each ethnic group and overall, the degree of carotid atherosclerosis was associated with a higher prevalence of cardiovascular disease. South Asians had the highest prevalence of this condition compared with Europeans and Chinese (11%, 5% and 2%, respectively; p=0.0004). Despite this finding, Europeans had more atherosclerosis (mean of the maximum intimal medial thickness 0.75 [0.16] mm) than South Asians (0.72 [0.15] mm) and Chinese (0.69 [0.16] mm). South Asians had an increased prevalence of glucose intolerance, higher total and low-density lipoprotein cholesterol, higher triglycerides and lower high-density lipoprotein cholesterol, and much greater abnormalities in novel risk factors including higher concentrations of fibrinogen, homocysteine, lipoprotein(a), and plasminogen activator inhibitor-1. Although there are differences in conventional and novel risk factors between ethnic groups, this variation and the degree of atherosclerosis only partly explains the higher rates of cardiovascular disease among South Asians compared with Europeans and Chinese. The increased risk of cardiovascular events could be due to factors affecting plaque rupture, the interaction between prothrombotic factors and atherosclerosis, or as yet undiscovered risk factors.

Adult↗

PubMedDate not supplied

Changes in acute myocardial infarction risk and patterns of practice for patients older and younger than 70 years, 1987-90.

OBJECTIVE: To evaluate temporal changes in risk and patterns of hospital practice for acute myocardial infarction (AMI). DESIGN/PATIENTS: Retrospective analysis of age-related medical therapy and outcome of 342 consecutive patients (132 at least 70 years old and 210 younger than 70) with AMI between July 1, 1989, and June 30, 1990, and comparison with data from two previous analyses of AMI practice in 1987 (n = 207) and 1988-89 (n = 402). SETTING: Tertiary care medical centre. INTERVENTIONS: No direct interventions; results of the two previous AMI practice pattern analyses, however, were propagated during the practice time of the most recent analysis. RESULTS: In 1989-90, hospital mortality was higher (19%) among patients at least 70 years old compared with patients younger than 70 (8%) (P less than 0.01). Therapies proven by repeated clinical trials to be effective in reducing AMI risk were all used less frequently in patients aged at least 70 years: thrombolysis (20 versus 43%); beta-blockers (41 versus 62%); acetylsalicylic acid (71 versus 87%); and nitrates (86 versus 97%). Qualitatively, these age-specific patterns of AMI mortality and therapy were similar to previous studies. Quantitatively, however, comparing 1987 with 1989-90 demonstrated parallel and marked increases in the use of all proven medications in both age groups, ranging from 42 to 230% (P less than 0.01). There was also a significant overall decrease in mortality from the 1987 patient cohort (20%) to the 1989-90 cohort (13%) (P less than 0.05). The decrease in mortality was entirely due to decreased mortality within the group 70 years or older; 35% in 1987 versus 19% in 1989-90 (P less than 0.05). Mortality in the AMI patients younger than 70 years old remained unchanged from 1987 to 1989-90. CONCLUSIONS: Pattern of practice analyses were associated with, and may have contributed to, improved patient care and outcomes in AMI. Increased use of effective AMI medical therapy had a greater benefit in elderly higher risk AMI patients than lower risk younger patients. Persisting age-specific differences in AMI therapy may respond to more direct quality improvement measures, such as critical path management.

Adrenergic beta-Antagonists↗

PubMedDate not supplied

Contemporary medical management of left ventricular dysfunction and congestive heart failure.

OBJECTIVE: The primary purpose of this review was to address the following question: based on the best available evidence, what should be the current medical management of congestive heart failure (CHF)? DATA SOURCES: The major sources for this review were from searches of the English language literature, including computer and bibliography reviews, of all randomized, controlled clinical trials and overview analyses of positive inotropic agents, preload/afterload reduction agents and beta-blocker medications in CHF. STUDY SELECTION: The number of studies reviewed was approximately 40. The major criterion for selection was that the studies be of CHF patients in randomized controlled clinical trials, particularly with a mortality/survival endpoint. Additional clinical trials of nonmortality endpoints in CHF patients and mortality trials in non-CHF patients were also selected to support possible pathophysiological insights for future CHF trials. DATA EXTRACTION: The data, particularly for the accompanying tables, were initially extracted by a single reviewer using common qualitative guidelines as far as was possible within the different temporal, etiological and geographic frameworks of the original component studies. Conclusions are drawn from this data synthesis and from published overviews. DATA SYNTHESIS: Angiotensin converting enzyme (ACE) inhibition therapy is effective in reducing mortality and morbidity in severe left ventricular dysfunction and CHF. Other systemic vasodilators may also be beneficial. The effects of digitalis on survival and morbidity in CHF are presently uncertain, but should be resolved in the near future. Other inotropic agents, at least in the long term, are clinically detrimental. Diuretics decrease morbidity, but their effect on mortality in CHF remains unknown. Beta-blocker and magnesium therapy offer promise in CHF, but await definitive clinical trials evaluation. CONCLUSIONS: The current medical therapy of CHF should definitely include ACE inhibitors, probably diuretics and possibly other vasodilators. Further viable trials of promising new, and older heretofore under-evaluated, CHF therapies are needed. Additionally, innovative strategies are needed to deal with this disease which has an increasing prevalence. Two strategies, primary prevention of CHF and a 'Heart Function Clinic', are discussed.

Adrenergic beta-Antagonists↗

PubMedDate not supplied

The changing clinical profile of coronary artery bypass graft patients, 1970-89.

OBJECTIVE: To review the changing clinical profile of isolated coronary artery bypass graft (CABG) surgery patients at the University of Alberta Hospitals during the past two decades. DESIGN: Data were obtained retrospectively by review of patients' hospital charts and cardiologists' charts. The three patient cohorts consisted of the first 411 consecutive patients who underwent isolated CABG surgery between 1970 and 1974, 302 consecutive patients who had CABG surgery in 1984 and 346 consecutive patients who had the operation in 1989. RESULTS: Patients who underwent CABG surgery in 1984 and 1989 were older than patients undergoing the same operation in the 1970s. Emergency and/or urgent operations and the number of patients with prior myocardial infarct were increased significantly in 1984 and 1989. The incidence of patients with multiple vessel disease and left main stem stenosis increased significantly over the two decades. The number of bypass grafts per patient and the use of internal mammary grafts have increased since 1970. The endarterectomy procedure was performed less frequently in 1984 and 1989. The use of radial artery grafts has been discontinued. Perioperative mortality remained stable throughout the study period despite an increasing incidence of high risk patients. The major cause of death was pump failure. The incidence of peripostoperative myocardial infarct was higher in the 1970s. A multivariate analysis of the 1984 and 1989 cohorts was performed to identify temporal trends in risk factors. Emergency surgery, preoperative heart failure, age (older than 65 years), prior CABG surgery and preoperative renal failure are significant predictors of operative motility. CONCLUSIONS: The clinical profile of patients for isolated CABG surgery has changed over the years. The mortality rate has been stable over two decades despite the advancement of medical and surgical practices, representing a balance of increasingly high risk patients presenting for CABG surgery.

Adult↗